Global Markets Direct's, 'Carcinomas - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Carcinomas, complete with latest updates, and special features on late-stage and discontinued projects.
https://www.reportscorner.com/reports/23246/Carcinomas-%E2%80%93-Pipeline-Review,-H1-2013/
Global Markets Direct's, 'Esophageal Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Esophageal Cancer, complete with latest updates, and special features on late-stage and discontinued projects.
https://www.reportscorner.com/reports/23243/Esophageal-Cancer-%E2%80%93-Pipeline-Review,-H1-2013/
This report provides comprehensive information on the therapeutic development for Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diarrhea and special features on late-stage and discontinued projects.
http://www.researchmoz.us/diarrhea-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the therapeutic development for Rhabdomyosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma and special features on late-stage and discontinued projects.
http://www.researchmoz.us/rhabdomyosarcoma-pipeline-review-h1-2015-report.html
Non alcoholic steatohepatitis - pipeline review, h1 2014Ambikabasa
This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects.
This report provides comprehensive information on the therapeutic development for Paroxysmal Nocturnal Hemoglobinuria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Paroxysmal Nocturnal Hemoglobinuria and special features on late-stage and discontinued projects.
http://www.researchmoz.us/paroxysmal-nocturnal-hemoglobinuria-pipeline-review-h1-2015-report.html
Esophageal cancer pipeline review, q3 2011linda3395
This report provides information on the therapeutic development for Esophageal Cancer, complete with latest updates, and special features on late-stage and discontinued projects.
This report provides comprehensive information on the therapeutic development for Traveler's Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traveler's Diarrhea and special features on late-stage and discontinued projects.
http://www.researchmoz.us/travelers-diarrhea-pipeline-review-h1-2015-report.html
Global Markets Direct's, 'Esophageal Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Esophageal Cancer, complete with latest updates, and special features on late-stage and discontinued projects.
https://www.reportscorner.com/reports/23243/Esophageal-Cancer-%E2%80%93-Pipeline-Review,-H1-2013/
This report provides comprehensive information on the therapeutic development for Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diarrhea and special features on late-stage and discontinued projects.
http://www.researchmoz.us/diarrhea-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the therapeutic development for Rhabdomyosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma and special features on late-stage and discontinued projects.
http://www.researchmoz.us/rhabdomyosarcoma-pipeline-review-h1-2015-report.html
Non alcoholic steatohepatitis - pipeline review, h1 2014Ambikabasa
This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects.
This report provides comprehensive information on the therapeutic development for Paroxysmal Nocturnal Hemoglobinuria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Paroxysmal Nocturnal Hemoglobinuria and special features on late-stage and discontinued projects.
http://www.researchmoz.us/paroxysmal-nocturnal-hemoglobinuria-pipeline-review-h1-2015-report.html
Esophageal cancer pipeline review, q3 2011linda3395
This report provides information on the therapeutic development for Esophageal Cancer, complete with latest updates, and special features on late-stage and discontinued projects.
This report provides comprehensive information on the therapeutic development for Traveler's Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traveler's Diarrhea and special features on late-stage and discontinued projects.
http://www.researchmoz.us/travelers-diarrhea-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the therapeutic development for Uveal Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveal Melanoma and special features on late-stage and discontinued projects.
http://www.researchmoz.us/uveal-melanoma-pipeline-review-h1-2015-report.html
Quantum genomics sa product pipeline review - 2015Ambikabasa
This report provides comprehensive information on the current therapeutic developmental pipeline of Quantum Genomics SAs, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
http://www.researchmoz.us/quantum-genomics-sa-product-pipeline-review-2015-report.html
This report provides information on the therapeutic development for Penile Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Penile Cancer.
This report provides comprehensive information on the therapeutic development for Raynauds Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Raynauds Disease and special features on late-stage and discontinued projects.
http://www.researchmoz.us/raynauds-disease-pipeline-review-h1-2015-report.html
In March 2011, the EMA and FDA launched a pilot program that aims at a parallel assessment by both agencies of certain quality/CMC sections which are relevant to Quality by Design (QbD). This voluntary pilot program is open. This presentation gives a summary of the FDA and EMA expectation for QbD submissions based on the pilot programme.
This report provides information on the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects.
ICH Guidelines were created by The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH aims to provide uniform standards for technical requirements for pharmaceuticals for human use. They are developed by regulatory and pharma industry authorities.
EU and US Procedures for API Registration - Commonalities and DifferencesMerck Life Sciences
View the interactive recording here: https://bit.ly/2PB0VZo
Abstract:
This webinar will review the current requirements for the active substance registration in the European Union and the USA. First, we will summarize the authority regulations for APIs in the EU and USA and show the similarities and differences of procedures such as CEP, AMSF, and US-DMF. Secondly, we’ll cover new trends and requirements for API-dossiers such as the control of elemental impurities according to the new international guideline ICH Q3D and related watchouts for CEPs. At the end of the presentation, we’ll discuss the eCTD roadmap for the future and the end of paper submissions.
This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects.
http://www.researchmoz.us/brain-cancer-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the therapeutic development for Uveal Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveal Melanoma and special features on late-stage and discontinued projects.
http://www.researchmoz.us/uveal-melanoma-pipeline-review-h1-2015-report.html
Quantum genomics sa product pipeline review - 2015Ambikabasa
This report provides comprehensive information on the current therapeutic developmental pipeline of Quantum Genomics SAs, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
http://www.researchmoz.us/quantum-genomics-sa-product-pipeline-review-2015-report.html
This report provides information on the therapeutic development for Penile Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Penile Cancer.
This report provides comprehensive information on the therapeutic development for Raynauds Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Raynauds Disease and special features on late-stage and discontinued projects.
http://www.researchmoz.us/raynauds-disease-pipeline-review-h1-2015-report.html
In March 2011, the EMA and FDA launched a pilot program that aims at a parallel assessment by both agencies of certain quality/CMC sections which are relevant to Quality by Design (QbD). This voluntary pilot program is open. This presentation gives a summary of the FDA and EMA expectation for QbD submissions based on the pilot programme.
This report provides information on the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects.
ICH Guidelines were created by The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH aims to provide uniform standards for technical requirements for pharmaceuticals for human use. They are developed by regulatory and pharma industry authorities.
EU and US Procedures for API Registration - Commonalities and DifferencesMerck Life Sciences
View the interactive recording here: https://bit.ly/2PB0VZo
Abstract:
This webinar will review the current requirements for the active substance registration in the European Union and the USA. First, we will summarize the authority regulations for APIs in the EU and USA and show the similarities and differences of procedures such as CEP, AMSF, and US-DMF. Secondly, we’ll cover new trends and requirements for API-dossiers such as the control of elemental impurities according to the new international guideline ICH Q3D and related watchouts for CEPs. At the end of the presentation, we’ll discuss the eCTD roadmap for the future and the end of paper submissions.
This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects.
http://www.researchmoz.us/brain-cancer-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the current therapeutic developmental pipeline of Genzyme Corporations, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
http://www.researchmoz.us/genzyme-corporation-product-pipeline-review-2015-report.html
This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects.
http://www.researchmoz.us/addiction-pipeline-review-h1-2015-report.html
Therapure biopharma inc. product pipeline review - 2015Ambikabasa
This report provides comprehensive information on the current therapeutic developmental pipeline of Therapure Biopharma Inc.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
http://www.researchmoz.us/therapure-biopharma-inc-product-pipeline-review-2015-report.html
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Myriad genetics, inc. product pipeline analysisraja1233
Companyprofilesandconferences.com glad to promote a new report on "Myriad Genetics, Inc. (MYGN) - Product Pipeline Analysis" which is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products who provides key information about the company, its major products and brands.
This report provides comprehensive information on the therapeutic development for Emphysema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Emphysema and special features on late-stage and discontinued projects.
http://www.researchmoz.us/emphysema-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the therapeutic development for Ocular Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Pain and special features on late-stage and discontinued projects.
http://www.researchmoz.us/ocular-pain-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the therapeutic development for Seborrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seborrhea and special features on late-stage and discontinued projects.
http://www.researchmoz.us/seborrhea-pipeline-review-h1-2015-report.html
Cook medical incorporated product pipeline analysisraja1233
Companyprofilesandconferences.com glad to promote a new report on "Cook Medical Incorporated - Product Pipeline Analysis" which is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products also provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Tillotts pharma ag product pipeline review - 2015Ambikabasa
This report provides comprehensive information on the current therapeutic developmental pipeline of Tillotts Pharma AGs, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
http://www.researchmoz.us/tillotts-pharma-ag-product-pipeline-review-2015-report.html
Similar to Carcinomas – pipeline review, h1 2013 - Reports Corner (20)
Therapeutic class overview treating refractory hematological malignancies - R...Reports Corner
Targeting unmet needs in the treatment of cancer/ hematological malignancies through innovative drug development strategies have witnessed favorable outcomes. Over the past decade, Proteasome inhibitor, Velcade (bortezomib) and the immunomodulatory drugs – Thalomid (thalidomide) and Revlimid (lenalidomide) have become the cornerstone of treatment for patients with Multiple Myeloma (MM) resulting in improved survival.
https://www.reportscorner.com/reports/37924/-THERAPEUTIC-CLASS-OVERVIEW:-TREATING-REFRACTORY-HEMATOLOGICAL-MALIGNANCIES/
Wireless security companies and solutions 2014 - ReportsCornerReports Corner
Overview:
Collectively speaking, wireless security represents technologies and solutions designed to prevent unauthorized access or information damage for computers connected to wireless networks.
https://www.reportscorner.com/reports/37807/Wireless-Security-Companies-and-Solutions-2014/
The cybersecurity market in nigeria to 2023 market brief - Reports Corner
Synopsis
SDI's "The Cybersecurity Market in Nigeria to 2023: Market Brief" provides a top-level, category specific view of the forecast market value of Cybersecurity expenditure in Nigeria.
Summary
SDI's "The Cybersecurity Market in Nigeria to 2023: Market Brief", provides a top-level, quantitative view of forecast expenditure of Cybersecurity sector in Nigeria. - Reports Corner
https://www.reportscorner.com/reports/27313/The-Cybersecurity-Market-in-Nigeria-to-2023:-Market-Brief/
The global military rotorcraft market 2013 2023 - Reports CornerReports Corner
Product Synopsis
This report is the result of SDI's extensive market and company research covering the global rotorcraft industry. It provides detailed analysis of both historic and forecast global industry values, factors influencing demand, the challenges faced by industry participants, analysis of the leading companies in the industry, and key news.
https://www.reportscorner.com/reports/27221/The-Global-Military-Rotorcraft-Market--2013-2023/
PSA Peugeot Citroen Automotive Company Profile, SWOT and Financial Report...Reports Corner
Synopsis
ICD Research's "PSA Peugeot Citroen : Automotive - Company Profile, SWOT and Financial Report" contains in depth information and data about the company and its operations.
https://www.reportscorner.com/reports/27219/PSA-Peugeot-Citroen-:-Automotive---Company-Profile,-SWOT-and-Financial-Report/
Renewable energy in germany - Reports CornerReports Corner
Introduction
Renewable Energy in Germany industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
https://www.reportscorner.com/reports/26823/Renewable-Energy-in-Germany/
Introduction
Textile Mills in India industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and
forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within
the market. Essential resource for top-line data and analysis covering the India textile mills market. Includes market size and segmentation data, textual
and graphical analysis of market growth trends, leading companies and macroeconomic information.
https://www.reportscorner.com/reports/23018/Textile-Mills-in-India/
Immunoglobulins market to 2019 demand in primary immunodeficiency (pi) and ...Reports Corner
GBI Research's report "Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer's Disease" provides in-depth analysis of the global immunoglobulin market. The report analyzes the markets for immunoglobulin products in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan.
https://www.reportscorner.com/reports/20855/Immunoglobulins-Market-to-2019---Demand-in-Primary-Immunodeficiency-(PI)-and-Chronic-Inflammatory-Demyelinating-Polyneuropathy-(CIDP)-Potentially-Supplemented-by-Approvals-for-Alzheimers-Disease/
Next generation network oss bss market and forecast 2013-2018 - Reports CornerReports Corner
"NGN promises a high quality end-user experience. Telecommunications service providers expect the NGN framework to provide them with tools that would ensure customer loyalty. However, the path towards achieving the ideal NGN is fraught with formidable challenges. The most critical challenge confronting operators is optimizing their OSS and BSS platforms, systems, and processes.
With research beginning in 2007, the report Next Generation Network OSS/BSS Market and Forecast 2013-2018 provides a comprehensive analysis of drivers and issues related to technical and business aspects of OSS/BSS deployments and developments while forecasting their growth over the next five years."
https://www.reportscorner.com/reports/20852/Next-Generation-Network-OSS/BSS-Market-and-Forecast-2013-2018/
The cbrn defense market 2013 2023 - Reports CornerReports Corner
"This report is the result of SDI's extensive market and company research covering the global CBRN defense industry. It provides detailed analysis of both historic and forecast global industry values, factors influencing demand, the challenges faced by industry participants, analysis of the leading companies in the industry, and key news.
"
https://www.reportscorner.com/reports/19410/The-CBRN-Defense-Market-2013-2023/
Indian in vitro diagnostics market opportunity analysis 2018 - Reports CornerReports Corner
The Indian IVD market is valued at more than US$ 500 Million, and is expected to touch the US$ 1 Billion in 2016 growing steady at a CAGR of 19%. This remarkable growth can be attributed to increased healthcare awareness, desire to undergo preventive health checkups, availability of disease specific tests, corporate setups promoting health focus of employees, and drift from manual to semi-automated and automated equipment.
https://www.reportscorner.com/reports/16265/Indian-In-Vitro-Diagnostics-Market-Opportunity-Analysis-2018/
Pharmaceutical market india a comprehensive industry analysis - Reports CornerReports Corner
"1.0 Summary
“Pharmaceutical Market: India, A Competitive Industry Analysis” by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle within domestic and international therapeutic markets. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.
The Indian pharmaceutical market is set to become the eight largest pharma market globally by 2015. In 2012 it was worth $13 billion. It is forecast to reach $50 billion by 2015 and increase its dominance as a leading player in Asia. It is predicted that the Indian pharma market will be a significant global competitor by 2020 with an expected worth of up to $74 billion.
This report describes the current therapeutics that are propelling the biopharmaceutical market in India. It examines the current economic climate and how India compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.
This study reveals market figures of the overall Indian pharmaceutical market and sub-markets. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.
https://www.reportscorner.com/reports/15826/Pharmaceutical-Market:-India-A-Comprehensive-Industry-Analysis/
Global pharmaceutical & biotechnology outlook 2013 japan pharma - Reports CornerReports Corner
The coming years will see Japan pharma regaining its status as innovator driven with Edoxaban for Daiichi Sankyo, Canagliflozin for Mitsubishi Tanabe, and Dolutegravir for Shionogi bringing the good times back for the respective companies in 2013 and carrying enough potential to change global market dynamics in the anticoagulant, diabetes and HIV space resp. We think that the massive ~$45b poured in acquiring innovation by Japanese companies does not justify its value as we find that the key catalysts from Japan are in-house candidates.
https://www.reportscorner.com/reports/10015/Global-Pharmaceutical-&-Biotechnology-Outlook-2013:-Japan-Pharma/
Global pharmaceutical & biotechnology outlook 2013 rising stars - Reports CornerReports Corner
Innovative and improved drugs therapies developed through novel target discovery and technology platforms have originated from the backyards of small research focused companies (Rising Stars, RS, non-profitable biotech companies). The universe continues to grow despite the high risk and the wait to transform into a successful profitable Mature Biotech is long.
https://www.reportscorner.com/reports/10016/Global-Pharmaceutical-&-Biotechnology-Outlook-2013:-Rising-Stars/
Mobile vas markets, applications, and opportunities third edition - Reports...Reports Corner
Mobile Value-added Service (VAS) applications represent a key aspect to the ongoing success of mobile network operators and everyone in the mobile communications value chain. With core services, such as bear voice and data communications becoming commodity offerings, wireless service providers are dependent on VAS applications to drive additional revenue and improved margins.
https://www.reportscorner.com/reports/15019/Mobile-VAS-Markets,-Applications,-and-Opportunities---Third-Edition/
The report provides a review and understanding of mergers and acquisitions (MandAs), capital-raising, partnering deals, and agreements entered into by defense companies during 2012.
03062024_First India Newspaper Jaipur.pdfFIRST INDIA
Find Latest India News and Breaking News these days from India on Politics, Business, Entertainment, Technology, Sports, Lifestyle and Coronavirus News in India and the world over that you can't miss. For real time update Visit our social media handle. Read First India NewsPaper in your morning replace. Visit First India.
CLICK:- https://firstindia.co.in/
#First_India_NewsPaper
31052024_First India Newspaper Jaipur.pdfFIRST INDIA
Find Latest India News and Breaking News these days from India on Politics, Business, Entertainment, Technology, Sports, Lifestyle and Coronavirus News in India and the world over that you can't miss. For real time update Visit our social media handle. Read First India NewsPaper in your morning replace. Visit First India.
CLICK:- https://firstindia.co.in/
#First_India_NewsPaper
In a May 9, 2024 paper, Juri Opitz from the University of Zurich, along with Shira Wein and Nathan Schneider form Georgetown University, discussed the importance of linguistic expertise in natural language processing (NLP) in an era dominated by large language models (LLMs).
The authors explained that while machine translation (MT) previously relied heavily on linguists, the landscape has shifted. “Linguistics is no longer front and center in the way we build NLP systems,” they said. With the emergence of LLMs, which can generate fluent text without the need for specialized modules to handle grammar or semantic coherence, the need for linguistic expertise in NLP is being questioned.
हम आग्रह करते हैं कि जो भी सत्ता में आए, वह संविधान का पालन करे, उसकी रक्षा करे और उसे बनाए रखे।" प्रस्ताव में कुल तीन प्रमुख हस्तक्षेप और उनके तंत्र भी प्रस्तुत किए गए। पहला हस्तक्षेप स्वतंत्र मीडिया को प्रोत्साहित करके, वास्तविकता पर आधारित काउंटर नैरेटिव का निर्माण करके और सत्तारूढ़ सरकार द्वारा नियोजित मनोवैज्ञानिक हेरफेर की रणनीति का मुकाबला करके लोगों द्वारा निर्धारित कथा को बनाए रखना और उस पर कार्यकरना था।
‘वोटर्स विल मस्ट प्रीवेल’ (मतदाताओं को जीतना होगा) अभियान द्वारा जारी हेल्पलाइन नंबर, 4 जून को सुबह 7 बजे से दोपहर 12 बजे तक मतगणना प्रक्रिया में कहीं भी किसी भी तरह के उल्लंघन की रिपोर्ट करने के लिए खुला रहेगा।
01062024_First India Newspaper Jaipur.pdfFIRST INDIA
Find Latest India News and Breaking News these days from India on Politics, Business, Entertainment, Technology, Sports, Lifestyle and Coronavirus News in India and the world over that you can't miss. For real time update Visit our social media handle. Read First India NewsPaper in your morning replace. Visit First India.
CLICK:- https://firstindia.co.in/
#First_India_NewsPaper
role of women and girls in various terror groupssadiakorobi2
Women have three distinct types of involvement: direct involvement in terrorist acts; enabling of others to commit such acts; and facilitating the disengagement of others from violent or extremist groups.
2. DescriptionDescription
Reports Cornerwww.reportscorner.com
Global Markets Direct's, 'Carcinomas - Pipeline Review, H1 2013',
provides an overview of the indication's therapeutic pipeline. This
report provides information on the therapeutic development for
Carcinomas, complete with latest updates, and special features
on late-stage and discontinued projects.
3. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Global Markets Direct's, 'Carcinomas - Pipeline Review, H1 2013',
provides an overview of the indication's therapeutic pipeline. This
report provides information on the therapeutic development for
Carcinomas, complete with latest updates, and special features
on late-stage and discontinued projects. It also reviews key
players involved in the therapeutic development for Carcinomas.
Carcinomas - Pipeline Review, Half Year is built using data and
information sourced from Global Markets Direct's proprietary
databases, Company/University websites, SEC filings, investor
presentations and featured press releases from
company/university sites and industry-specific third party
sources, put together by Global Markets Direct's team.
Note*: Certain sections in the report may be removed or altered
based on the availability and relevance of data for the indicated
disease.
4. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Scope
- A snapshot of the global therapeutic scenario for Carcinomas.
- A review of the Carcinomas products under development by
companies and universities/research institutes based on
information derived from company and industry-specific sources.
- Coverage of products based on various stages of development
ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and
combined therapeutics.
- Coverage of the Carcinomas pipeline on the basis of route of
administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
5. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Reasons to buy
- Identify and understand important and diverse types of
therapeutics under development for Carcinomas.
- Identify emerging players with potentially strong product
portfolio and design effective counter-strategies to gain
competitive advantage.
- Plan mergers and acquisitions effectively by identifying players
of the most promising pipeline.
- Devise corrective measures for pipeline projects by
understanding Carcinomas pipeline depth and focus of Indication
therapeutics.
- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects
to enhance and expand business potential and scope.
6. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
- Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from
pipeline.
7. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Carcinomas Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Carcinomas 11
Carcinomas Therapeutics under Development by Companies 13
Carcinomas Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
8. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Carcinomas Therapeutics – Products under Development by Companies 20
Carcinomas Therapeutics – Products under Investigation by Universities/Institutes 21
Companies Involved in Carcinomas Therapeutics Development 22
Sequella, Inc. 22
Eli Lilly and Company 23
GlaxoSmithKline plc 24
Merck & Co., Inc. 25
Takara Holdings Inc. 26
Aduro BioTech 27
Bayer AG 28
Momenta Pharmaceuticals, Inc. 29
9. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
PCI Biotech AS 30
Nanobiotix 31
Cancer Research Technology Limited 32
Spectrum Pharmaceuticals, Inc. 33
Telormedix SA 34
Cellceutix Corporation 35
Viventia Biotechnologies Inc. 36
Lytix Biopharma AS 37
Carcinomas – Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 45
cetuximab - Drug Profile 45
10. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Product Description 45
Mechanism of Action 45
R&D Progress 45
cixutumumab - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ridaforolimus - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
(amphinex + bleomycin sulfate) - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
11. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
M-402 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ramucirumab - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
ramucirumab - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
SQ-109 - Drug Profile 69
Product Description 69
Mechanism of Action 69
12. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
R&D Progress 69
SPI-1620 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
imiquimod - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
oportuzumab monatox - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Kevetrin - Drug Profile 77
Product Description 77
13. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Mechanism of Action 77
R&D Progress 77
HF-10 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
NPI-1342 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
MOC31-PE - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
LTX-315 - Drug Profile 83
14. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Product Description 83
Mechanism of Action 83
R&D Progress 83
aspirin - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
nelfinavir mesylate - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
GV-1001 + LTX-315 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
15. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
bevacizumab + [cisplatin] + Radiation Therapy - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
LMP Specific Cytotoxic T-Lymphocytes - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
bevacizumab + [fluorouracil] + [leucovorin calcium] + [oxaliplatin] - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
lambrolizumab - Drug Profile 90
Product Description 90
Mechanism of Action 90
16. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
R&D Progress 90
cidofovir - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
BAY-94-9343 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
ANZ-100 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
LY-2510924 - Drug Profile 95
Product Description 95
17. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Mechanism of Action 95
R&D Progress 95
dasatinib + [erlotinib hydrochloride] + [gemcitabine hydrochloride] - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
interleukin-15 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
interferon alfa-2b biosimilar - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Anti-S100A4 Monoclonal Antibody - Drug Profile 100
18. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Product Description 100
Mechanism of Action 100
R&D Progress 100
NBTX-IV - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Platinum Based Compounds - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
PMA-104R - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
19. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Carcinomas Therapeutics – Drug Profile Updates 104
Carcinomas Therapeutics – Discontinued Products 126
Carcinomas Therapeutics - Dormant Products 127
Carcinomas – Product Development Milestones 130
Featured News & Press Releases 130
May 01, 2013: GSK Announces FDA Extension Of PDUFA Date For Trametinib By Three Months 130
Jun 29, 2012: Topotarget Announces Top-Line Results From Phase II Trial Of Belinostat For Treatment Of
Cancer 130
Oct 04, 2011: Fresenius Biotech Obtains Reimbursement Approval For Removab Antibody In Belgium 131
Sep 19, 2011: Spectrum Announces Positive First Part Of Phase I Study Results Of SPI-1620 In
Carcinomas 131
Jun 14, 2011: ImmunoGen Earns Milestone With BAY 94-9343 IND Submission 132
Jun 07, 2011: Fresenius Biotech Presents New Data Of Trifunctional Antibody Removab At ASCO 133
Jun 07, 2011: Fresenius Biotech Presents New Data Of Trifunctional Antibody Removab At ASCO 134
May 26, 2011: ImmunoGen Announces Clinical Presentation Of IMGN901 At ASCO 2011 Annual Meeting
135
20. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Apr 04, 2011: ImmunoGen Announces First Data For New Therapeutic For Ovarian Cancer And Other
Carcinomas 135
Apr 04, 2011: Curis Announces Investigator-Initiated Phase II Study Results Presented At 102nd AACR
Annual Meeting 2011 136
Appendix 138
Methodology 138
Coverage 138
Secondary Research 138
Primary Research 138
Expert Panel Validation 138
Contact Us 139
Disclaimer 139
21. For more informationFor more information
Reports Cornerwww.reportscorner.com
For more information please visit our website
https://www.reportscorner.com/reports/23246/Carcinomas-%E2%80%93-Pipeline-
Review,-H1-2013/